Investigating pacritinib for treating relapsed or refractory T-cell lymphomas
Pacritinib in rel/refr T-cell lymphomas
This study is looking at how well a new drug called pacritinib works for people with tough-to-treat T-cell lymphomas, aiming to find better ways to help them feel better and manage their cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10918196 on NIH RePORTER |
What this research studies
This research focuses on patients with relapsed or refractory T-cell lymphomas, a type of cancer that is difficult to treat with existing therapies. The study aims to explore the effectiveness of pacritinib, a drug that targets specific signaling pathways involved in the growth and survival of malignant T cells. By understanding how these pathways interact and contribute to the disease, the research seeks to develop a more effective treatment strategy. Patients may be monitored for their response to the drug and any changes in their condition throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with relapsed or refractory T-cell lymphomas.
Not a fit: Patients with early-stage T-cell lymphomas or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with T-cell lymphomas who have not responded to current therapies.
How similar studies have performed: Other research has shown promise in targeting similar pathways in T-cell lymphomas, suggesting that this approach may lead to meaningful advancements in treatment.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Wilcox, Ryan a — University of Michigan at Ann Arbor
- Study coordinator: Wilcox, Ryan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.